Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialAxel Hauschild, Paul B. Chapman, Piotr Rutkowski et al.|The Lancet|2012Cited by 3k
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialGeorgina V. Long, Dirk Schadendorf, Uwe Trefzer et al.|The Lancet Oncology|2012Cited by 906
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part oneAndreas Lundqvist, James Geib, Vincent van Hoef et al.|Journal for ImmunoTherapy of Cancer|2016Cited by 11